Intangible Assets (Narrative) (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|
Aug. 14, 2023 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Jun. 30, 2023 |
Aug. 23, 2021 |
|
| Finite-Lived Intangible Assets [Line Items] | |||||||
| Impairment of intangible assets | $ 565,000 | ||||||
| Amortization of Intangible Assets | $ 5,000 | $ 49,000 | $ 10,000 | $ 116,000 | |||
| Patents and Licenses | |||||||
| Finite-Lived Intangible Assets [Line Items] | |||||||
| Impairment of intangible assets | $ 25,000 | $ 565,000 | |||||
| RubrYc Therapeutics Inc | Immune-Oncology Antibodies (RTX-003) | |||||||
| Finite-Lived Intangible Assets [Line Items] | |||||||
| Investment | $ 7,500,000 | ||||||
| X | ||||||||||
- Definition The amount of investment under the stock purchase agreement. No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|